*Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston; †Department of Otology and Laryngology, Harvard Medical School, Boston; ‡Program in Speech and Hearing Bioscience and Technology, Harvard Medical School and Massachusetts Institute of Technology, Cambridge; and §Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, U.S.A.
Otol Neurotol. 2014 Feb;35(2):353-7. doi: 10.1097/MAO.0000000000000189.
Given the presence of a pathological immune response in sporadic vestibular schwannoma (sVS), this study aims to explore the roles of aspirin in minimizing sVS growth in vivo.
Retrospective case review.
Tertiary care hospital.
People diagnosed with sVS and followed at a tertiary referral center by serial magnetic resonance imaging (MRI) for at least 4 months within the period of January 1980 through April 2012.
Patient use of aspirin and sVS growth rate measured by changes in the largest tumor dimension as noted on serial MRIs
Within a set of 689 cases, 347 were followed by serial MRI scans (50.3%); of the latter, 81 took aspirin, of which, 33 demonstrated sVS growth, and 48 did not. Of the 266 nonaspirin users, 154 demonstrated sVS growth, and 112 did not. A significant inverse association was found among aspirin users and sVS growth (odds ratio [OR]: 0.50, 95% confidence interval [CI]: 0.29-0.85), which was not confounded by age or sex.
Our results suggest a potential therapeutic role of aspirin in inhibiting sVS growth.
鉴于散发性前庭神经鞘瘤（sVS）存在病理性免疫反应，本研究旨在探讨阿司匹林在体内最小化 sVS 生长中的作用。
回顾性病例研究。
三级保健医院。
1980 年 1 月至 2012 年 4 月期间，在三级转诊中心通过连续磁共振成像（MRI）至少随访 4 个月诊断为 sVS 的患者。
患者使用阿司匹林情况和 sVS 生长率，通过连续 MRI 上最大肿瘤尺寸的变化来衡量。
在一组 689 例患者中，有 347 例接受了连续 MRI 扫描（50.3%）；其中 81 例服用了阿司匹林，其中 33 例显示 sVS 生长，48 例没有。在 266 例非阿司匹林使用者中，有 154 例显示 sVS 生长，112 例没有。阿司匹林使用者与 sVS 生长之间存在显著的负相关关系（优势比[OR]：0.50，95%置信区间[CI]：0.29-0.85），这与年龄或性别无关。
我们的结果表明阿司匹林在抑制 sVS 生长方面具有潜在的治疗作用。
